Metabolic Reprogramming in Anticancer Drug Resistance: A Focus on Amino Acids.
amino acids
anticancer drug resistance
cancer metabolism
Journal
Trends in cancer
ISSN: 2405-8025
Titre abrégé: Trends Cancer
Pays: United States
ID NLM: 101665956
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
08
01
2021
revised:
12
02
2021
accepted:
16
02
2021
pubmed:
20
3
2021
medline:
4
1
2022
entrez:
19
3
2021
Statut:
ppublish
Résumé
Overcoming anticancer drug resistance is a major challenge in cancer therapy, requiring innovative strategies that consider the extensive tumor heterogeneity and adaptability. We provide recent evidence highlighting the key role of amino acid (AA) metabolic reprogramming in cancer cells and the supportive microenvironment in driving resistance to anticancer therapies. AAs sustain the acquisition of anticancer resistance by providing essential building blocks for biosynthetic pathways and for maintaining a balanced redox status, and modulating the epigenetic profile of both malignant and non-malignant cells. In addition, AAs support the reduced intrinsic susceptibility of cancer stem cells to antineoplastic therapies. These findings shed new light on the possibility of targeting nonresponding tumors by modulating AA availability through pharmacological or dietary interventions.
Identifiants
pubmed: 33736962
pii: S2405-8033(21)00046-7
doi: 10.1016/j.trecan.2021.02.004
pii:
doi:
Substances chimiques
Amino Acids
0
Antineoplastic Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
682-699Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Interests S.M.F. has received funding from Bayer AG, Merck, and Black Belt Therapeutics, and has consulted for Fund +. The other authors declare no conflicts of interest.